Table 1. Clinical characteristics of DIPG patients.
| Patient ID | Age (y) | Gender | Symptom duration (w) | Treatment at diagnosis | Treatment at disease progression | PFS (m) | OS (m) |
|---|---|---|---|---|---|---|---|
| 1 | 5.0 | M | <6 | XRT (15×3=45 Gy) | - | 8 | 8 |
| 2 | 9.0 | F | 12-24 | XRT (16×2.8 = 44.8 Gy) | Temozolomide | 28 | 41 |
| 3 | 1.3 | F | 12-24 | - | Vincristine, carboplatin | 2 | 11 |
| 4 | 7.5 | M | <6 | XRT (13×3.0=39 Gy) + temozolomide | - | 5 | 6 |
| 5 | 7.2 | M | <6 | XRT (30×1.8=54Gy) + gemcitabine / HDC / combined targeted therapy | Temozolomide, imatinib, dichloroacetate | 12 | 20 |
| 6 | 14.7 | M | <6 | XRT (6×3.0=18 Gy) | - | 1 | 6 |
| 7 | 11.1 | M | <6 | XRT (13×3.0=39 Gy) | XRT (8×3.0=24 Gy) | 12 | 17 |
| 8 | 10.5 | M | <6 | XRT (13×3.0=39 Gy) | XRT (10×3.0=30 Gy) | 2 | 15 |
| 9 | 12.3 | F | <6 | XRT (30×1.8=54Gy) + gemcitabine | - | 1 | 4 |
M: male, F: female, y: years, m: months, w: weeks, h: hours, XRT: radiotherapy, HDC: high-dose chemotherapy, PFS: progression-free survival, OS: overall survival